tiprankstipranks
Trending News
More News >
Medpace Holdings Inc (MEDP)
:MEDP
US Market
Advertisement

Medpace Holdings (MEDP) Stock Forecast & Price Target

Compare
643 Followers
See the Price Targets and Ratings of:

MEDP Analyst Ratings

Hold
10Ratings
Hold
1 Buy
7 Hold
2 Sell
Based on 10 analysts giving stock ratings to
Medpace
Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MEDP Stock 12 Month Forecast

Average Price Target

$524.89
▼(-11.40% Downside)
Based on 10 Wall Street analysts offering 12 month price targets for Medpace Holdings in the last 3 months. The average price target is $524.89 with a high forecast of $655.00 and a low forecast of $425.00. The average price target represents a -11.40% change from the last price of $592.46.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","386":"$386","476":"$476","566":"$566","656":"$656"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":655,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$655.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":524.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$524.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$425.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,386,476,566,656],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.91,590.3015384615385,595.6930769230769,601.0846153846154,606.4761538461538,611.8676923076923,617.2592307692307,622.6507692307692,628.0423076923076,633.4338461538462,638.8253846153846,644.2169230769231,649.6084615384616,{"y":655,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.91,580.2930769230769,575.6761538461539,571.0592307692308,566.4423076923076,561.8253846153846,557.2084615384615,552.5915384615384,547.9746153846154,543.3576923076923,538.7407692307692,534.1238461538461,529.506923076923,{"y":524.89,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,584.91,572.6092307692307,560.3084615384615,548.0076923076923,535.7069230769231,523.4061538461539,511.1053846153846,498.8046153846154,486.50384615384615,474.2030769230769,461.90230769230766,449.60153846153844,437.3007692307692,{"y":425,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":319.56,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":342.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":473.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.91,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$655.00Average Price Target$524.89Lowest Price Target$425.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on MEDP
BMO Capital
BMO Capital
$600
Hold
1.27%
Upside
Initiated
11/12/25
Medpace initiated with a Market Perform at BMO CapitalMedpace initiated with a Market Perform at BMO Capital
Truist Financial Analyst forecast on MEDP
Truist Financial
Truist Financial
$555
Hold
-6.32%
Downside
Reiterated
10/27/25
Truist Financial Sticks to Their Hold Rating for Medpace Holdings (MEDP)
Mizuho Securities Analyst forecast on MEDP
Mizuho Securities
Mizuho Securities
$575$655
Buy
10.56%
Upside
Reiterated
10/24/25
Medpace price target raised to $655 from $575 at MizuhoMedpace price target raised to $655 from $575 at Mizuho
Robert W. Baird Analyst forecast on MEDP
Robert W. Baird
Robert W. Baird
$491$613
Hold
3.47%
Upside
Reiterated
10/24/25
Medpace price target raised to $613 from $491 at BairdMedpace price target raised to $613 from $491 at Baird
TD Cowen
$356$462
Sell
-22.02%
Downside
Reiterated
10/24/25
Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning
William Blair Analyst forecast on MEDP
William Blair
William Blair
Hold
Reiterated
10/23/25
Medpace Holdings: Strong Q3 Performance Amid Valuation and Growth Sustainability Concerns
Barclays Analyst forecast on MEDP
Barclays
Barclays
$425
Sell
-28.27%
Downside
Reiterated
10/23/25
Barclays Remains a Sell on Medpace Holdings (MEDP)
Leerink Partners Analyst forecast on MEDP
Leerink Partners
Leerink Partners
$455$490
Hold
-17.29%
Downside
Reiterated
10/08/25
Leerink Partners Keeps Their Hold Rating on Medpace Holdings (MEDP)
Jefferies Analyst forecast on MEDP
Jefferies
Jefferies
$400$450
Hold
-24.05%
Downside
Reiterated
09/08/25
Jefferies Reaffirms Their Hold Rating on Medpace Holdings (MEDP)
Rothschild & Co Redburn Analyst forecast on MEDP
Rothschild & Co Redburn
Rothschild & Co Redburn
$342$474
Hold
-19.99%
Downside
Downgraded
09/03/25
Redburn Atlantic downgrades Medpace Holdings (MEDP) to a HoldRothschild Redburn analyst Jamie Clark downgraded Medpace (NASDAQ: MEDP) from Buy to Neutral with a price target of $474.00 (from $342.00).
UBS
$300$305
Sell
-48.52%
Downside
Downgraded
07/29/25
Medpace downgraded to Sell from Neutral at UBSMedpace downgraded to Sell from Neutral at UBS
Deutsche Bank  Analyst forecast on MEDP
Deutsche Bank
Deutsche Bank
$270$430
Hold
-27.42%
Downside
Reiterated
07/23/25
Medpace price target raised to $430 from $270 at Deutsche BankMedpace price target raised to $430 from $270 at Deutsche Bank
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on MEDP
BMO Capital
BMO Capital
$600
Hold
1.27%
Upside
Initiated
11/12/25
Medpace initiated with a Market Perform at BMO CapitalMedpace initiated with a Market Perform at BMO Capital
Truist Financial Analyst forecast on MEDP
Truist Financial
Truist Financial
$555
Hold
-6.32%
Downside
Reiterated
10/27/25
Truist Financial Sticks to Their Hold Rating for Medpace Holdings (MEDP)
Mizuho Securities Analyst forecast on MEDP
Mizuho Securities
Mizuho Securities
$575$655
Buy
10.56%
Upside
Reiterated
10/24/25
Medpace price target raised to $655 from $575 at MizuhoMedpace price target raised to $655 from $575 at Mizuho
Robert W. Baird Analyst forecast on MEDP
Robert W. Baird
Robert W. Baird
$491$613
Hold
3.47%
Upside
Reiterated
10/24/25
Medpace price target raised to $613 from $491 at BairdMedpace price target raised to $613 from $491 at Baird
TD Cowen
$356$462
Sell
-22.02%
Downside
Reiterated
10/24/25
Medpace Holdings: Overvaluation Concerns Amid Growth Projections and Market Positioning
William Blair Analyst forecast on MEDP
William Blair
William Blair
Hold
Reiterated
10/23/25
Medpace Holdings: Strong Q3 Performance Amid Valuation and Growth Sustainability Concerns
Barclays Analyst forecast on MEDP
Barclays
Barclays
$425
Sell
-28.27%
Downside
Reiterated
10/23/25
Barclays Remains a Sell on Medpace Holdings (MEDP)
Leerink Partners Analyst forecast on MEDP
Leerink Partners
Leerink Partners
$455$490
Hold
-17.29%
Downside
Reiterated
10/08/25
Leerink Partners Keeps Their Hold Rating on Medpace Holdings (MEDP)
Jefferies Analyst forecast on MEDP
Jefferies
Jefferies
$400$450
Hold
-24.05%
Downside
Reiterated
09/08/25
Jefferies Reaffirms Their Hold Rating on Medpace Holdings (MEDP)
Rothschild & Co Redburn Analyst forecast on MEDP
Rothschild & Co Redburn
Rothschild & Co Redburn
$342$474
Hold
-19.99%
Downside
Downgraded
09/03/25
Redburn Atlantic downgrades Medpace Holdings (MEDP) to a HoldRothschild Redburn analyst Jamie Clark downgraded Medpace (NASDAQ: MEDP) from Buy to Neutral with a price target of $474.00 (from $342.00).
UBS
$300$305
Sell
-48.52%
Downside
Downgraded
07/29/25
Medpace downgraded to Sell from Neutral at UBSMedpace downgraded to Sell from Neutral at UBS
Deutsche Bank  Analyst forecast on MEDP
Deutsche Bank
Deutsche Bank
$270$430
Hold
-27.42%
Downside
Reiterated
07/23/25
Medpace price target raised to $430 from $270 at Deutsche BankMedpace price target raised to $430 from $270 at Deutsche Bank
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medpace Holdings

1 Month
xxx
Success Rate
5/9 ratings generated profit
56%
Average Return
+4.87%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +4.87% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
+6.24%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +6.24% per trade.
1 Year
Ann HynesMizuho Securities
Success Rate
6/7 ratings generated profit
86%
Average Return
+37.23%
reiterated a buy rating last month
Copying Ann Hynes's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +37.23% per trade.
2 Years
xxx
Success Rate
7/7 ratings generated profit
100%
Average Return
+53.84%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +53.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MEDP Analyst Recommendation Trends

Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
10
11
9
5
4
Hold
14
13
13
9
10
Sell
2
2
3
4
4
Strong Sell
0
0
0
0
0
total
26
26
25
18
18
In the current month, MEDP has received 4 Buy Ratings, 10 Hold Ratings, and 4 Sell Ratings. MEDP average Analyst price target in the past 3 months is 524.89.
Each month's total comprises the sum of three months' worth of ratings.

MEDP Financial Forecast

MEDP Earnings Forecast

Next quarter’s earnings estimate for MEDP is $4.19 with a range of $4.09 to $4.35. The previous quarter’s EPS was $3.86. MEDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MEDP has Performed in-line its overall industry.
Next quarter’s earnings estimate for MEDP is $4.19 with a range of $4.09 to $4.35. The previous quarter’s EPS was $3.86. MEDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MEDP has Performed in-line its overall industry.

MEDP Sales Forecast

Next quarter’s sales forecast for MEDP is $689.40M with a range of $678.50M to $708.58M. The previous quarter’s sales results were $659.90M. MEDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MEDP has Performed in-line its overall industry.
Next quarter’s sales forecast for MEDP is $689.40M with a range of $678.50M to $708.58M. The previous quarter’s sales results were $659.90M. MEDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MEDP has Performed in-line its overall industry.

MEDP Stock Forecast FAQ

What is MEDP’s average 12-month price target, according to analysts?
Based on analyst ratings, Medpace Holdings Inc’s 12-month average price target is 524.89.
    What is MEDP’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MEDP, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is MEDP a Buy, Sell or Hold?
        Medpace Holdings Inc has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 2 sell ratings.
          What is Medpace Holdings Inc’s price target?
          The average price target for Medpace Holdings Inc is 524.89. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $655.00 ,the lowest forecast is $425.00. The average price target represents -11.40% Decrease from the current price of $592.46.
            What do analysts say about Medpace Holdings Inc?
            Medpace Holdings Inc’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of MEDP?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis